Tyler C. Liu

Tyler C. Liu is a patent litigation attorney with a primary focus on pharmaceutical and biotechnology matters, including those brought under the Hatch-Waxman Act. As counsel in Sterne, Kessler, Goldstein & Fox's Biotechnology & Chemical Practice Group, his expertise spans the life sciences sector. His academic background, including an M.S. in Biochemistry and Molecular Biology, further underscores this specialization.

Liu primarily represents defendants, specifically operating and generic pharmaceutical companies facing patent assertions. All five of his tracked appearances are on the defendant side. He was notably part of the team representing Halozyme Inc. as a defendant in cases such as Unified Patents v. Halozyme Inc. and Merck Sharp & Dohme LLC v. Halozyme Inc. Beyond these, he represented Dexcel Pharma in a patent litigation settlement with Pfizer Inc. concerning VYNDAMAX® patents, and secured a Federal Circuit victory for Hopewell Pharma Ventures in a dispute with Merck's EMD Serono unit involving the drug MAVENCLAD.

Liu possesses extensive experience in Patent Trial and Appeal Board (PTAB) proceedings, including the preparation and filing of inter partes review (IPR) petitions, representing both patent owners and petitioners. Before joining Sterne Kessler, he gained in-house experience at a generic pharmaceutical company, where he managed strategic planning for IPR matters and drafted petitions and expert declarations. He has co-authored articles discussing strategies for establishing compelling merits at the PTAB.

Tyler C. Liu earned his J.D. from The George Washington University Law School, an M.S. in Biochemistry and Molecular Biology from Georgetown University, and a B.A. from the University of California, Berkeley. He is admitted to practice in the District of Columbia, Texas, and before the U.S. Patent & Trademark Office.